Microba Life Sciences (MAP) Investor Update summary

Financial Performance and Guidance

• FY25 revenue forecasted at AUD 15.4 million–16 million, reflecting over 145% year-on-year growth for core testing products and 28–33% overall YoY growth.

• Regional break-even targeted in Australia and the UK by end of FY2026, with group EBITDA break-even as a strategic objective.

• Q3 saw 26% quarter-on-quarter growth in Australia; 18% average quarterly growth needed to meet FY2026 targets.

• Growth model leverages scalable, product-led strategies to drive operating leverage and margin expansion.

• Key assumptions include continued clinician adoption, stable pricing, and sufficient capital for expansion.

Capital Raising and Strategic Investment

• Raised AUD 14.5 million through an institutional placement and a fully underwritten share purchase plan, with placement priced at $0.09 per share and free attaching options.

• Up to $8.3 million new investment from Sonic Healthcare, with total Sonic investment reaching $30.1 million over three years.

• Sonic’s participation structured in three tranches, including options exercisable at a premium and subject to shareholder approval.

• Strategic partnership with Sonic’s UK subsidiary, The Doctors Laboratory, to handle UK lab processing, reducing CapEx and OpEx.

• Proceeds will accelerate commercialisation of core tests, expand clinical adoption, and strengthen working capital.

Market Opportunity and Growth Strategy

• Addressable market estimated at $25 billion, targeting 82 million global patients with GI disease.

• Serviceable obtainable market is 2 million tests per annum in top five focus markets, with a cash-pay model.

• Only a small fraction of the market needs to be captured to meet internal targets.

• Product adoption is mapped along a skepticism curve, targeting innovator and early adopter clinicians.

• Product roadmap includes quarterly feature releases to address clinician needs and drive adoption.